Sickle Cell Disease patients need to be monitored routinely to treat symptoms due to the complications of the condition. Side eﬀects differ between individuals and are managed differently. A team of different healthcare professionals work together collaboratively to monitor the symptoms as they occur, and management systems are put in place by interdisciplinary teams.
According to Kapoor, Sargam et al (2018), the treatment therapies currently available for SCD are red blood cell transfusion and Hydroxyurea. Hematopoietic stem cell or bone marrow transplant is curative, but there are a lot of barriers to this treatment option, including; lack of suitable donors, immunologic transplant rejection, long-term adverse eﬀects, prognostic uncertainty, and poor end-organ function, which is especially problematic for older patients. Gene therapy to correct the gene mutation is under investigation as another curative option.